Loader

Pathways

PathWhiz ID Pathway Meta Data

PW145820

Pw145820 View Pathway
drug action

Sulconazole Drug Metabolism Action Pathway

Homo sapiens

PW132603

Pw132603 View Pathway
metabolic

Sulfabenzamide Drug Metabolism

Homo sapiens
Sulfabenzamide is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Sulfabenzamide passes through the liver and is then excreted from the body mainly through the kidney.

PW146111

Pw146111 View Pathway
drug action

Sulfabenzamide Drug Metabolism Action Pathway

Homo sapiens

PW128400

Pw128400 View Pathway
drug action

Sulfacetamide Action Pathway

Escherichia coli (strain K12)
Sulfacetamide is an anti-infective agent from the sulfonamide drug class (antibiotic). This drug can be used topically to treat skin infections (acne vulgaris), as well as orally to treat urinary tract infections. It is also indicated in the treatment of bacterial vaginitis, keratitis, acute conjunctivitis, and blepharitis. Sulfacetamide is a bacteriostatic drug, it stops the replication of the bacteria. This molecule binds to the dihydropteroate synthase protein in a wide-spectrum activity against most gram-positive and many gram-negative organisms. The inhibited enzyme is essential for the synthesis of folic acid from para-aminobenzoic acid (PABA) molecules. Folic acids are essential for the growth of the bacteria.

PW132601

Pw132601 View Pathway
metabolic

Sulfacetamide Drug Metabolism

Homo sapiens
Sulfacetamide is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Sulfacetamide passes through the liver and is then excreted from the body mainly through the kidney.

PW144748

Pw144748 View Pathway
drug action

Sulfacetamide Drug Metabolism Action Pathway

Homo sapiens

PW128407

Pw128407 View Pathway
drug action

Sulfacytine Action Pathway

Escherichia coli (strain K12)
Sulfacytine is a short-acting antibiotic from the sulfonamide drug class. This drug class consists of synthetic bacteriostatic antibiotics with a broad spectrum against most gram-positive and many gram-negative organisms. Sulfacytine is indicated in the treatment of acute urinary tract infections. Sulfacytine inhibits the multiplication of bacteria by acting as a competitive inhibitor of dihydropteroate synthase in the folic acid metabolism cycle. This enzyme does the condensation of the pteridine with the para-aminobenzoic acid (PABA). The inhibition causes the bacteria to stop growing. This drug is administered as an oral tablet but was discontinued in 2006 (FDA).

PW145365

Pw145365 View Pathway
drug action

Sulfacytine Drug Metabolism Action Pathway

Homo sapiens

PW144485

Pw144485 View Pathway
drug action

Sulfadiazine Drug Metabolism Action Pathway

Homo sapiens

PW176136

Pw176136 View Pathway
metabolic

Sulfadiazine Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Sulfadiazine are predicted with biotransformer.